ROARABLE
FREE $100K
Today Screener Big Ideas Track Record ๐Ÿ’ฐ $100K Arena ๐ŸŽฒ Predictions ๐Ÿ›๏ธ Insiders 8 Analysts
Stock Ratings / Health Care / PAVM / options
MODD (33) RVP (31) CTSO (22) GUTS (34) โŒ˜ Pro Terminal โ†’

PAVmed Inc. (PAVM) Options Positioning, Max Pain & Unusual Sweeps

$1.91 -2.05% NASDAQ โ€ข Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.90

PAVmed Inc. (PAVM) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E โ€ข RED ALERT Cap $15.6M
๐Ÿ“ค Share Live RQD Speedometer Card: ๐• Post Reddit StockTwits โฌ‡ Live SVG Card
โšก INSTANT AI QUANT PREVIEW โ€ข $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PAVM Below โ€” or Connect Your Own ChatGPT / Claude
๐Ÿค– Mara Quenwick โ€ข AI Quant Lead (Click for Instant Brief) Is PAVM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
โ–ผ

As of 2026-11-03, PAVmed Inc. (NASDAQ: PAVM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.91 (-2.05% 1D, market cap $15.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PAVM ranks #869 in composite RQD confidence.

โœ“ Pre-computed one-to-many AI Quant brief
๐Ÿค– Ellis Vennor โ€ข AI Peer & Flow Quant (Click for Instant Brief) How does PAVM compare to MODD and RVP in the Health Care sector?
โ–ผ

Within the Health Care sector (Medical/Dental Instruments), PAVM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MODD (Modular Medical Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and RVP (Retractable Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -23.3%, cap $16.9M). Among the 5-stock peer group, PAVM leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).

โœ“ Pre-computed one-to-many AI Quant brief
๐Ÿค– Gideon Ashmere โ€ข AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PAVM?
โ–ผ

Per PAVM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001624326), PAVmed Inc. generated $71.0K in revenue (-97.6% YoY), -$3.8M in net income, and -$5.2M in free cash flow against $38.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

โœ“ Pre-computed one-to-many AI Quant brief
๐Ÿค– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists โ€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
๐Ÿ›ก๏ธ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.90 (-0.56%)๐Ÿงฌ Dilution Drag (+1.28% YoY Shares)โš™๏ธ Cash Engine: 8/20 (D-) โ€ข 0% FCF Margin
Verify 90D Bucket Audit โ†’
๐Ÿ“Š Historical Track Record Warning: Scores below 50 (28/100 ยท E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY โ€ข 29.0% hit rate).
Audit Bucket Track Record โ†’
RQD QUANT TACHOMETERRED ALERT โ€ข E
025507510028
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0โ€“100 RQD rubric) โ€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E ยท Rk D-
Cash (8)Whales (3)SEC (8)Macro (6)CEO (3)
Each axis scored 0โ€“20
12M PRICE TARGET CONE-13.6% Base Target
$30 Bull$2 Base$1 Bear
๐Ÿ“ฌ FREE PAVM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: โ€” (No Active Options Snapshot on file for PAVM)Realized 20D OHLCV Swing Band: ยฑ12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
๐Ÿ” WHY PAVM SCORES 28/100 (E) โ€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
โ–ฒ #1 Bullish Driver: Cash Engine Quality+8/20 pts (29% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

โ–ฒ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) โ€ข Piotroski F-Score 1/9

โ–ผ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

๐Ÿ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 โ†’ Q2 โ†’ Q3 โ†’ Current
Q1 (-3Q)
36
Grade E$2.64-15.5% Next Q
Q2 (-2Q)
33
Grade E$2.23-4% Next Q
Q3 (-1Q)
31
Grade E$2.14-10.7% Next Q
Current
28
Grade E$1.91-10% Hist 90D ฮฑ
Trajectory: E (36) โ†’ E (28)Full Audit โ†’
โš”๏ธ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

โš”๏ธ Adversarial Opposing Case: What Could Spark a PAVM Turnaround Squeeze

Gideon Ashmere Forensic Desk โ†’

While PAVM currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

๐Ÿš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

๐Ÿš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.44) and Max Pain ($2.01) forces dealer call-delta covering toward $29.86.

๐Ÿš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

๐ŸŽฒ LIVE PREDICTION MARKET ODDS TIED TO $PAVMโ€ข $2.4M Crowd Pool โ€ข Kalshi / Polymarket Composite
Contract: โ€œPAVM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMAโ€
YES 28%NO 72%Trade / Inspect Odds โ†’
CALL VS. PUT WHALE SHARE
โ€” (No Active Options Snapshot)
Put/Call Ratio: โ€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
โ€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
ยฑ12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (PAVM)

โ€” (No Active Options Snapshot) โ€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for PAVM.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

๐Ÿ† Enter Free $100K Paper Arena โ†’
ON-DEMAND RQD QUANT WORKSHOP โ€ข SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PAVM)

  • โœ“Walkthrough of PAVM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • โœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • โœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) โ†’$100K Arena
PAVM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -76.51%๐Ÿ›ก๏ธ HOLDING TREND SUPPORT
2026-11-03O $1.97H $1.97L $1.91C $1.91VOL 6.6K
RES: $4.39SUP: $1.52SMA50: $3.44SMA200: $6.51
$11.95$9.21$6.47$3.73$0.99RES $4.39SUP $1.52$1.912026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PAVM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

๐Ÿฆ‹ PAVM Butterfly Map โ†’ + Track PAVM โ†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -97.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PAVM today. View full Setup Ledger โ†’

๐Ÿฆ‹ Documented & Second-Order Butterfly Connections Open Graph โ†’

No direct multi-tier Butterfly edges indexed yet for PAVM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
๐ŸŽฌ No recent verified company-specific video clip queued for PAVM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk โ†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT โ€ข SEC EDGAR XBRL ร— RQD PEER BENCHMARK

๐Ÿ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PAVM)

Health Care Rank #869 of 1015 โš”๏ธ MODD vs PAVM Full Matrix โ†’

1. Head-to-Head Health Care Peer Comparison (PAVM vs. MODD, RVP, CTSO, GUTS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, PAVmed Inc. (PAVM) ranks #869 by composite RQD confidence (28/100, grade E) and #851 by equity capitalization ($15.6M). Within this direct 5-issuer industry benchmark cohort, PAVM leads on earnings valuation at N/A trailing P/E, while RVP leads on capital efficiency and profitability with -23.3% ROIC and 0.1% gross margin. GUTS currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with PAVM at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PAVM ACTIVE
PAVmed Inc.
E 28/100 โ€” -30.0% -35.0% -2.05% $15.6M Benchmark Subject
MODD
Modular Medical Inc.
E 33/100 โ€” โ€” -35.0% +4.65% $16.3M /modd-vs-pavm โ†’
RVP
Retractable Technologies Inc.
E 31/100 โ€” 0.1% -23.3% +0.18% $16.9M /rvp-vs-pavm โ†’
CTSO
Cytosorbents Corporation
E 22/100 โ€” 71.5% -35.0% -9.25% $14.3M /ctso-vs-pavm โ†’
GUTS
Fractyl Health Inc.
E 34/100 โ€” โ€” -35.0% -3.47% $13.0M /guts-vs-pavm โ†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023โ€“FY2025)

SEC EDGAR 10-K โ€ข FILED 2025-12-31 โ€ข CIK 0001624326 โ†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PAVmed Inc. (PAVM) reported GAAP revenue of $71.0K (-97.6% vs. FY2024 revenue of $3.0M , and -97.1% cumulative change since FY2023) , GAAP net income of -$3.8M, operating cash flow of -$5.2M, and free cash flow of -$5.2M (+84.4% YoY). On the balance sheet, PAVM closed FY2025 with $38.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $71.0K -$3.8M -$5.2M -$5.2M $38.8M โ€”
FY2024 (FY) 2024-12-31 $3.0M $32.0M -$33.6M -$33.6M $30.7M โ€”
FY2023 (FY) 2023-12-31 $2.5M -$66.3M -$52.0M -$52.0M โ€” โ€”

3. PAVM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

โœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PAVM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, PAVmed Inc. (NASDAQ: PAVM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.91 (-2.05% 1D, market cap $15.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PAVM ranks #869 in composite RQD confidence.

How does PAVM compare to MODD and RVP in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PAVM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MODD (Modular Medical Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and RVP (Retractable Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -23.3%, cap $16.9M). Among the 5-stock peer group, PAVM leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PAVM?

Per PAVM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001624326), PAVmed Inc. generated $71.0K in revenue (-97.6% YoY), -$3.8M in net income, and -$5.2M in free cash flow against $38.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PAVM trading relative to its 50-day, 200-day, and 52-week technical levels?

PAVM last traded at $1.91 (-2.05% on volume of 6,431 shares), positioning the stock -44.48% below its 50-day simple moving average ($3.44) and -70.66% below its 200-day simple moving average ($6.51). Across its 52-week range of $1.84 to $28.44, PAVM sits at the 0.3% percentile with a 14-day RSI of 27.1 (OVERSOLD (<32)) and an implied next-earnings move of ยฑ12.5% ($1.67 to $2.15).

Direct Sub-Reports: PAVM RQD Cockpit PAVM 12M Forecast PAVM Earnings & Move PAVM Dividends & DRIP PAVM Insiders & 13F PAVM Whale Options PAVM Profit Sankey PAVM News & Why
ROARABLE RATING BRIEF โ€ข RQD 28/100 (E) โœ“ SEC XBRL & RQD VERIFIED

PAVM โ€” PAVmed Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

PAVmed Inc. (PAVM) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.91 (-2.05% 1D, market capitalization $15.6M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of -30.0%, operating margin of -60.0%, and free cash flow yield of โ€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical/Dental Instruments industry. The profile reports a market capitalization of $0.0B, which is inconsistent with the $15.8M shown in market data, so the market data figure is used elsewhere in this dossier. โ€” for product lines, customers, or revenue model specifics.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), PAVmed Inc. (PAVM) reported $71.0K in annual revenue (up from $3.0M in FY2024, -97.6% YoY) and -$3.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.5M revenue, -$66.3M net income) through FY2025, PAVM scaled operating cash flow to -$5.2M and free cash flow to -$5.2M, backed by $38.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • ๐Ÿ‚ Primary Bull Case (E โ€ข RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of โ€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.84 โ€“ $28.44 52-week range.
  • ๐Ÿป Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain is NONE, with no upstream or downstream links and no proprietary signals recorded. No upstream supplier, downstream customer, or sector-correlation ripples can be mapped from the source data. The only sector reference is Health Care / Medical/Dental Instruments. โ€” for second-order bottlenecks.

  • Key Question #1: Can PAVM sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $71.0K and free cash flow of -$5.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PAVM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PAVM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PAVmed Inc. (PAVM) โ€ข Click "Debate This Headline" to argue it in the Roar Pit below

๐Ÿ’ฌ Jump to PAVM Debate Forum (3) โ†“
๐Ÿ”ฅ THE ROAR PIT โ€ข LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PAVM Bull vs. Bear Conversation Board โ€” What's Your Call at $1.91?

๐Ÿ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PAVM ๐Ÿป 33% BEARISH CONVICTION
1. Pick Your Side on PAVM:
๐Ÿ’ก Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER โ€ข Fundamental Long-Only ๐Ÿ‚ BULLISH ๐ŸŽฏ Target: $2.24 (+14.9%)
๐Ÿ“Œ Pinned Debate

The stock trades at $1.97 near its 52-week low of $1.84 and a $15.8M market cap, leaving room for a rebound if the $15M Lucid Diagnosti

The stock trades at $1.97 near its 52-week low of $1.84 and a $15.8M market cap, leaving room for a rebound if the $15M Lucid Diagnostics Series C raise stabilizes operations.. When you look under the hood at PAVM, Fundamental Cash Engine is 8/20 with -30.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $28.44. My 12M target is $2.24.

RetailWhale_TX ๐Ÿ‚ BULL

@ForensicBear Shorting a 3/20 institutional whale-flow stock at $1.95 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER โ€ข 10-K Footnote Auditor ๐Ÿป BEARISH ๐ŸŽฏ Target: $1.62 (-16.9%)
Spot @ $1.95

Negative ROIC of -35%, a 0% FCF yield, a Piotroski F-Score of 1 of 9, and revenue falling to $0.1M in FY 2025 indicate weak fundamental

Careful chasing PAVM at $1.95. Negative ROIC of -35%, a 0% FCF yield, a Piotroski F-Score of 1 of 9, and revenue falling to $0.1M in FY 2025 indicate weak fundamentals with no institutional or insider support.. Gross margin is -30.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.62 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%